All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): E7090
Therapeutic Area: Oncology Product Name: E7090
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DS-6000
Therapeutic Area: Oncology Product Name: DS-6000
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Sarah Cannon Research Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
First patient has been dosed in comapny's first-in-human phase 1 study evaluating DS-6000, a CDH6 directed antibody drug conjugate (ADC), in patients with advanced renal cell carcinoma or ovarian cancer with disease progression following standard treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Datopotamab deruxtecan
Therapeutic Area: Oncology Product Name: DS-1062
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2021
Details:
Updated results from the TROPION-PanTumor01 phase 1 trial showed promising clinical activity for datopotamab deruxtecan. DESTINY-Lung01 phase 2 trial showed preliminary evidence of antitumor activity for ENHERTU, a HER2 directed ADC, in patients with metastatic NSCLC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Trastuzumab Deruxtecan,Nivolumab
Therapeutic Area: Oncology Product Name: Enhertu
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
First data to show that ENHERTU may be safely combined with an immunotherapy agent, at therapeutic doses of both agents and for a meaningful treatment duration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DS-1055
Therapeutic Area: Oncology Product Name: DS-1055
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
First-in-human phase 1 study to evaluate DS-1055 as a new type of immune intervention for patients with relapsed/refractory advanced or metastatic solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Patritumab Deruxtecan
Therapeutic Area: Oncology Product Name: U3-1402
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
HER3 directed ADC demonstrates clinical activity in patients with EGFR-mutated metastatic or unresectable NSCLC previously treated with a tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy in first presentation of dose expansion data for patritumab deruxtecan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eribulin Mesylate
Therapeutic Area: Oncology Product Name: E7389-LF
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
E7389-LF is a new formulation using liposomes made of a lipid bilayer to encapsulate the halichondrin-class microtubule dynamics inhibitor eribulin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STA551
Therapeutic Area: Oncology Product Name: STA551
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
Non-clinical research results on STA551, the world's first Switch Antibody using Chugai's proprietary antibody engineering technology Switch-Ig®, was accepted for publication in the world’s leading journal in oncology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DS-1062
Therapeutic Area: Oncology Product Name: DS-1062
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $6,000.0 million Upfront Cash: $1,000.0 million
Deal Type: Collaboration July 27, 2020
Details:
The Collaboration is Aimed at Developing and Commercialising DS-1062, Around the World, Except in Japan, Where Daiichi Sankyo Will Hold the Exclusive Rights to Manufacture and Supply DS-1062
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
